On May 8, the FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy. For more information, read the FDA announcement and the Partner Therapeutics press release.
On May 8, the FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy.
For more information, read the FDA announcement and the Partner Therapeutics press release.
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
